Literature DB >> 1956037

Synthesis and anti-HIV-1 activity of 4,5,6,7-tetrahydro-5-methylimidazo[4,5,1-jk][1,4]benzodiazepin-2(1H)-on e (TIBO) derivatives. 2.

M J Kukla1, H J Breslin, C J Diamond, P P Grous, C Y Ho, M Miranda, J D Rodgers, R G Sherrill, E De Clercq, R Pauwels.   

Abstract

In the first paper of this series a new structure with anti-HIV-1 activity was disclosed and analogues were synthesized to explore the structure-activity relationship of changes in the substituent (R) attached at the N-6 position of 9. This study describes the syntheses and anti-HIV-1 testing of analogues with variations of the five-membered urea ring of the 4,5,6,7-tetrahydro-5-methylimidazo[4,5,1-jk] [1,4]benzodiazepin-2(1H)-one (TIBO) structures. Although many different rings were synthesized to replace the cyclic urea of TIBO, most were found to be inactive in inhibiting the replication of the HIV-1 virus in MT-4 cells. The exceptions were replacement of the urea oxygen with sulfur or selenium to give the corresponding thio- or selenoureas. These were found to be more active than the oxygen counterparts. A small series of analogues was synthesized and tested which allowed direct comparison of urea and thiourea derivatives. Without exception, the latter were always more active than the former. The most active compound of this series (8d) was found to inhibit the HIV-1 virus with an IC50 of 0.012 microM which is comparable to that of AZT.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1956037     DOI: 10.1021/jm00115a007

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  3 in total

1.  Quantitative structure-activity relationships and comparative molecular field analysis of TIBO derivatised HIV-1 reverse transcriptase inhibitors.

Authors:  S Hannongbua; P Pungpo; J Limtrakul; P Wolschann
Journal:  J Comput Aided Mol Des       Date:  1999-11       Impact factor: 3.686

2.  Synthesis and anticancer activity of new hydroxamic acid containing 1,4-benzodiazepines.

Authors:  Lawrence P Tardibono; Marvin J Miller
Journal:  Org Lett       Date:  2009-04-02       Impact factor: 6.005

3.  New tetrahydroimidazo[4,5,1-jk][1,4]-benzodiazepin-2(1H)-one and -thione derivatives are potent inhibitors of human immunodeficiency virus type 1 replication and are synergistic with 2',3'-dideoxynucleoside analogs.

Authors:  R Pauwels; K Andries; Z Debyser; M J Kukla; D Schols; H J Breslin; R Woestenborghs; J Desmyter; M A Janssen; E De Clercq
Journal:  Antimicrob Agents Chemother       Date:  1994-12       Impact factor: 5.191

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.